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Adult onset Still’s disease (AOSD) is an autoimmune disease characterized by systemic inﬂammation and
is a rarely reported cause of pulmonary arterial hypertension (PAH). We describe the clinical course of a
40-year-old woman who presented with PAH 19 months after a diagnosis of AOSD. Sildenaﬁl and
immunosuppressive therapy with cyclosporine resulted in clinical and hemodynamic improvement with
long-term survival 15 years after her initial presentation of AOSD. We review the literature for published
cases of PAH due to AOSD and discuss the potential mechanisms relating inﬂammatory diseases and PAH.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adult-onset Still’s disease (AOSD) is a rare inﬂammatory auto-
immune disease of unknown etiology characterized by fever,
arthritis, evanescent maculopapular rash, lymphadenopathy, hep-
atosplenomegaly, elevated liver enzymes, leukocytosis, hyper-
ferritinemia, negative antinuclear antibodies (ANA) and a negative
rheumatoid factor (RF) [1]. In a signiﬁcant minority of patients,
there is an associated macrophage activation syndrome present.
Pulmonary arterial hypertension (PAH) is a disease of the pulmo-
nary arterioles resulting in progressive elevation in pulmonary
arterial pressure and pulmonary vascular resistance, which can
lead to right heart failure and death [2]. PAH is frequently associ-
ated with autoimmune and connective tissue diseases (CTD) suchPAH, pulmonary arterial hy-
id factor; SLE, systemic lupus
ssure; IL, interleukin; WHO,
ization; mPAP, mean pulmo-
ance; 6MWD, 6-minute walk
factor of activated T cells.
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mixed CTD but has only rarely been associated with AOSD [3].
Perivascular inﬂammation, dysregulated immune cells and
elevated cytokine levels have been implicated in the pathogenesis
of PAH and may be a mechanism by which autoimmune diseases,
including AOSD, result in PAH [4]. We present a case of PAH asso-
ciated with AOSD with an excellent long-term response to cyclo-
sporine and sildenaﬁl over 15 years of follow-up.2. Case presentation
A 40-year-old woman from Korea presented in 2001 with
recurrent fevers, arthralgia of her ankles and knees, and a salmon
coloured rash on her arms and trunk. Laboratory investigations
were consistent with AOSD: erythrocyte sedimentation rate of
81 mm/h, ferritin level of 422 mg/L, alkaline phosphatase 400 U/L,
alanine aminotransferase 475 U/L and splenomegaly on ultrasound.
Hepatitis C antibodies, ANA, RF and anti-double stranded DNA
antibodies were not detected. Bone marrow aspiration and biopsy
showed a hypercellular marrow, with an increased number of
histiocytes, but only minimal evidence of hemophagocytosis.
Shortly after the diagnosis of AOSD in October 2001, an echocar-
diogramwas performed showing normal cardiac function and right
ventricular systolic pressure (RVSP) in the normal range atnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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anti-inﬂammatory agents for 4 months but experienced persis-
tent fevers, arthralgia and fatigue. She was then started on the
interleukin (IL)-1 receptor antagonist, anakinra, with improvement
but incomplete resolution in symptoms of AOSD. In July of 2003 she
presented with progressive dyspnea, rated as World Health Orga-
nization (WHO) function class III, pedal edema and hypoxemia. At
that time her treatment consisted of prednisone 15 mg/d and
anakinra 100 mg injections subcutaneously daily.
Her physical examination revealed a Cushingoid appearance,
blood pressure 130/70 mm Hg, heart rate 80 beats per minute,
respiratory rate 20/min, and oxygen saturation 93% with 2 L/min
supplemental oxygen. Her jugular venous pulsation was seen near
the earlobe when sitting at 90. There was a parasternal heave,
wide splitting of the second heart sound with a loud pulmonic
component, and a murmur consistent with tricuspid regurgitation.
Her lungs were clear to auscultation. Peripheral leg edema was
present and a palpable spleen tip was noted on abdominal
examination.
Investigations revealed a low probability ventilation perfusion
scan, no evidence of interstitial or parenchymal lung disease on a
computed tomography scan of the chest, and splenomegaly on
abdominal ultrasound without hepatic enlargement. Human im-
munodeﬁciency virus serology was negative. Pulmonary function
testing revealed normal spirometry and lung volumes with an
isolated low diffusion capacity for carbon monoxide of 39% pre-
dicted. A right heart catheterization (RHC) was then performed,
which conﬁrmed pre-capillary PAH: mean pulmonary artery pres-
sure (mPAP) 39 mm Hg, pulmonary artery wedge pressure (PAWP)
7 mm Hg, cardiac output 4.8 L/min, pulmonary vascular resistance
(PVR) 532 dynes$sec$cm5. There was no signiﬁcant hemodynamic
response to inhaled nitric oxide at 40 parts permillion. Her baseline
6-minute walk distance (6MWD) was 104 m.
Anakinra was discontinued and she was treated with intrave-
nous furosemide and bosentan 62.5 mg B.I.D, which was titrated to
125 mg B.I.D. after 4 weeks. In May of 2004 she presented with
decompensated right heart failure, a pericardial effusion and clin-
ical evidence of a ﬂare of AOSD. Prednisone and cyclosporine
150 mg B.I.D were initiated in hospital. Due to the interaction be-
tween bosentan and cyclosporine, bosentan was discontinued. In
September of 2004, with immunosuppression alone, her 6MWD
improved to 190m (see Fig.1), at which point sildenaﬁl 75mg Q.I.D.Fig. 1. Change in 6-minute walk diswas added. She continued with cyclosporine, oral furosemide and
4 L/min oxygen. By January 2005, she had experienced marked
clinical improvement to WHO functional class II, had decreasing
oxygen requirements to 2 L/min and further increase in her 6MWD
to 340 m. Between 2005 and 2015 she remained clinically stable
with no further hospitalizations for PAH or right heart failure. She
currently has mild exercise intolerance (WHO functional class II),
improved mPAP, cardiac index and PVR from baseline (Table 1) and
requires oxygen only for nocturnal hypoxemia. She has remained
on sildenaﬁl 75mg Q.I.D and the dose of cyclosporinewas gradually
reduced to 50mg twice daily with clinical and laboratory remission
of AOSD and sustained improvement in 6MWD (Fig. 1).3. Discussion
We have described a patient who developed PAH 19 months
after the diagnosis of AOSD and experienced long-term survival
with sustained clinical and hemodynamic responses to cyclo-
sporine and sildenaﬁl. Other potential causes of pulmonary hy-
pertension (PH) including left heart disease, chronic
thromboembolic pulmonary hypertension, and interstitial lung
disease, were excluded at the time of PAH diagnosis. Her mani-
festations of AOSD subsequently ﬂared necessitating initiation of
immunosuppression with prednisone and cyclosporine, which
resulted in clinical improvement. The addition of high-dose sil-
denaﬁl (75 mg Q.I.D.) to cyclosporine 4 months later resulted in
improved functional status and 6MWD, which have been sustained
over a 13-year period (Fig. 1). Hemodynamic reassessments in 2005
and 2007 demonstrated mild increases in mPAP, which was pre-
dominantly post-capillary in nature and improved cardiac index
(Table 1). She had several echocardiograms and a cardiac magnetic
resonance study showing no signiﬁcant left sided dysfunction or
valve disease. Possible explanations for the elevated PAWP at
follow-up include left ventricular diastolic dysfunction secondary
to interventricular septal shift from the elevated right ventricular
end-diastolic pressure, or ﬂuid overload from cyclosporine-induced
sodium retention. The most recent RHC in 2015 showed hemody-
namic improvement compared to all previous measurements. This
is the ﬁrst reported case of AOSD associated PAH demonstrating
long-term survival and clinical response to a combination of a PAH-
speciﬁc pulmonary vasodilator and immunosuppression.
The association of PAH with rheumatic disease and CTD such astance and treatment regimen.
Table 1
Changes in hemodynamic parameters between initial presentation and November 2015.
Hemodynamic parameter Date
Jul-03 Aug-05 Aug-07 Nov-15
Central venous pressure (mm Hg) 9 22 16 10
Pulmonary artery pressure (mm Hg) 62/23 (mean 39) 92/36 (mean 55) 72/37 (mean 50) 51/26 (mean 35)
Pulmonary artery wedge pressure (mm Hg) 7 17 21 14
Cardiac output (L/min) 4.8 5.6 5.2 6.79
Cardiac index (L/min/m2) 2.4 3 2.78 3.23
Pulmonary vascular resistance (dynes$sec$cm5) 532 614 446 276.9
Pulmonary vascular resistance index (dynes$sec$cm5$m2) 1065 1145 834 582.5
Mixed venous O2 saturation (%) 59 65 61 66.6
Table 2
Summary of reported cases of pulmonary arterial hypertension associated with adult onset Still’s disease.
Author
[reference]
Age
(years)
Sex Interval between AOSD and
PAH diagnosis
RHC conﬁrmation
of PAH
Treatment Outcome
Zen A [5] 29 F 2.5 years Y Not speciﬁed Not speciﬁed
Chen CH [6] 41 F 2 years N Not speciﬁed Not speciﬁed
27 F 2 years N Not speciﬁed Not speciﬁed
Thakare M
[8]
18 F 2 weeks N Steroids þ NSAIDS Not speciﬁed
Mubashir E
[7]
29 F 9 years Y Prednisone, Nifedipine 60 mg/d and Anakinra Died 2.5 months after Dx
Mehta M
[11]
30 F Not speciﬁed Y Treprostinil, ambrisentan, cyclosporine,
anakinra and prednisone
Improved at 1 month
Kadavath S
[10]
38 F 10 months Y Tocilizumab, Methotrexate, Steroids. Alive at 1 year
Campos M
[9]
27 F 7 years Y Amlodipine and anakinra Improved at 18 months. Sustained
improvement at 11 years
AOSD: Adult Onset Still’s Disease; PAH: pulmonary arterial hypertension; RHC: right heart catheterization performed; F: female; Y: Yes; N: No; NSAIDS: non-steroidal anti-
inﬂammatory; Dx: diagnosis.
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[3]. The association of PAHwith AOSD is less clear, with only 8 other
cases identiﬁed in the literature between 1990 and April 2016
(Table 2). In 1990, Zen et al. described the ﬁrst case of a 29-year-old
woman who presented with rapidly progressive pre-capillary pul-
monary hypertension 2.5 years after her diagnosis of AOSD [5]. In a
series of 19 patients with autoimmune-associated PAH in Taiwan, 2
female patients of 27 and 41 years old had AOSD [6]. Although
echocardiographic estimates of right ventricular systolic pressure
were severely elevated in both cases (102 and 105 mm Hg), he-
modynamic conﬁrmation of pre-capillary PAH was not reported.
Another case described a 29-year-old womanwho developed PAH 9
years after her AOSD diagnosis and died 2.5 months later despite
treatment with nifedipine, prednisone and anakinra [7]. An 18-
year-old woman presented with new-onset AOSD, pulmonary hy-
pertension and a pericardial effusion just 7 months after the onset
of symptoms, however RHC conﬁrmation of pre-capillary PAH was
not reported [8]. Campos and Schiopu described a 27-year-old with
severe PAH and AOSD who responded dramatically to anakinra,
with sustained improvement in both AOSD and PAH after 5 years of
treatment [9]. The use of tocilizumab, an IL-6 antagonist, was highly
effective in the treatment of a 38-year-old woman who developed
PAH while on treatment with anakinra [10]. Another more recent
case described a 30-year-old woman who presented with severe
PAH, right ventricular failure and cardiogenic shock in the context
of AOSD, macrophage activation syndrome and non-speciﬁc inter-
stitial pneumonia [11]. This patient was treated with a regimen of
anakinra, cyclosporine, prednisone, treprostinil and ambrisentan
with clinical improvement and stability at 1-month follow-up.
The role of inﬂammation and abnormal immunologic responses
in the development of PAH is incompletely understood, however,
targeting the inﬂammatory component of PAH pathobiology is anarea of active interest [4]. Patients with PAH and AOSD have
elevated levels of inﬂammatory cytokines including IL-1, IL-6, and
tumour necrosis factor-alpha, which are upregulated by nuclear
factor of activated T cells (NFAT) [4,12]. Cyclosporine and tacrolimus
are calcineurin inhibitors, which target NFAT and may reverse PAH
in animals [12]. By reducing both pro-inﬂammatory cytokines and
inhibiting bone morphogenic protein receptor 2 signalling, calci-
neurin inhibitors may also result in clinical beneﬁts in patients with
PAH, although further clinical studies are necessary [12,13]. A study
by Jaïs et al. reported a 57% response rate using cyclophosphamide
plus vasodilator therapies in PAH associated with SLE and mixed
CTD, whereas 3 of 8 patients treated with immunosuppression
alone had relapsed PAH and required additional PAH-speciﬁc
therapy [14]. The excellent long-term clinical response in our case
illustrates the potential role of immunosuppression with cyclo-
sporine in combination with pulmonary arterial vasodilators for
PAH associated with AOSD. Given the rarity of AOSD-related PAH
and poor outcomes in most published cases, the current authors
suggest an aggressive approach to treatment with immunosup-
pression and PAH-speciﬁc vasodilator therapy.Conﬂicts of interest
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